Buprenorphine is a medication for opioid use disorder that reduces mortality. This study aims to investigate the less well-understood relationship between the dose in the early stages of treatment and the subsequent risk of death.

Researchers compared the average daily dose of buprenorphine (transmucosal) during the first 30 days after initiation with mortality rates over the subsequent year. Data was obtained from Kentucky databases for 47,857 patients.

Higher First 30-Day Dose of Buprenorphine for Opioid Use Dis… : Journal of Addiction Medicine (lww.com)